Momenta Pharma (MNTA) Posts Q3 Loss of $0.38, Tops by 2c
More News related to MNTA
- Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Fourth Quarter and Year Ended 2009 Financial Results
- Momenta Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
- Momenta Pharmaceuticals (MNTA) volatility flat into FDA decision
- BioCentury Publishes BioTech Picks for FY10 (HGSI, VRTX, AMGN, More...)
- BioCentury Publishes Investor Picks for New Biotech Bellwethers in 2010
More News related to Earnings
- US Postal Service Announces Q1 Loss of $297M; Sees Mail Volume Falling 5.6% in '10
- NYSE Euronext (NYX) Beats the Street's Q4 Views on Both the Top and Bottom Lines
- Traders Cheering Agrium's (AGU) Q4 Bottom Line Beat
- Highlights From HIG's Q4 Conference Call: Q4 Represented a Return to Profitability; Guides In-line for FY10
- Highlights From ERTS's Q3 Conference Call: Releasing Several New Titles, But Guides Below Street Consensus
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) reports Q3 loss of $0.38, 2 cents better than the analyst estimate of ($0.40). Revenue for the quarter was $4 million, which compares to the estimate of $4.74 million.
Related Categories
EarningsStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
